22 Penis cancer

Penis cancer

10

THE GEC ESTROHANDBOOKOF BRACHYTHERAPY | Part II Clinical Practice Version 1 - 15/07/2022

TABLE 1 SELECTED RESULTS FOR LDR AND PDR INTERSTITIAL PENILE BRACHYTHERAPY Author/year n LDR vs. PDR Dose (Gy) F/up (mo) LC:5y (10y)

CSS 5y

complications Penis intact

Achkari 2020[21]

20% necrosis 21% stenosis 0 necrosis 2/23 stenosis 12% necrosis 9% stenosis 23% necrosis 45% stenosis 21% necrosis 25% stenosis 8% necrosis 44% stenosis 3 necrosis 19% stenosis 4% necrosis 43% stenosis 21% necrosis 5% stenosis ns

65

PDR

37(3-120)

85% (3y)

ns

85% (3y)

60

Chaudhary 1999[27] Crook 2008[28] Delannes 1992[29] Delaunay 2013[30] Escande 2017(14) Kiltie 2000[31] Mazeron 1984[32] Pimenta 2015[33] Rozan 1995[34] Soria 1997[35]

23

LDR

50

21 (4-117)

70%

70% (8y)

LDR 26 PDR 41

87%(5y) 72(10y)

84% (10 y)

88% (5y) 67%(10y)

67

60

48 (4-194)

51

LDR

50-65

65 (12-144)

86% crude

85%

75%

47

LDR

60

80(13-190)

81%

87%

60%

LDR 166 PDR 35

201

65

128

82%

85%

31

LDR

63.5

61.5

81%

85%

75%

50

LDR

60-70

36-96

78% crude

74%

LDR 14 PDR 10

24

60

110

96%

91%

86%

184

LDR

63

139

86%

88%

78%

102

LDR

61-70

111

77%

ns

ns

72% (6y)

F/up(mo): Followup (months), LC 5y(10y): Local Control at 5 years (10 year results in brackets), CSS 5y: Cause specific survival at 5 years

TABLE 2 SELECTED RESULTS FOR HDR INTERSTITIAL PENILE BRACHYTHERAPY

Daily dose (GyX2/day)

Penile preserv n

Author (year) n

F/up months Total dose Gray

LC

CSS 5-year

Toxicity

Pohankova 2019 [24]

77% (83% 5y)

Necrosis 4% (amputation)

26

85 (7-200)

54

3 X 2

100%

73%

Sharma 2014[23] Rouscoff 2014[26]

G2 fibrosis 29% Hyperpig 14% 93%

14

22 (6-40)

42-45

3 X 2

12/14

83% (3 yr)

Necrosis 9% Telangiect 33% G2 fibrosis 9% Necrosis 3% Stenosis 1% Hyperpig 35%

4- 4.34 X 2

12

27(5-83)

36-39

92%

100%

92%

Kellas-Slekza 2019 (25)

3-3.5 X 2

76

76 (7-204)

49(30-54)

73%

85%

70%

Necrosis 43% Stenosis 43% Telangiectasia 67%

Marban 2020(19)

3.12-3.75 X 2

7

90 (11-106)

38.4-53

86%

100%

86%

Martz 2021[36]

29

72 (3-174)

35-39

3.89-4.33

82%

88%

Necrosis 10% 79%

F/up: Followup, LC: Local Control, CSS: Cause specific survival, preservn: preservation, Hyperpig: hyperpigmentation, telangiect: telangiectasia